Page 35 - Noble-Virtual-Healthcare-2024

IN8bio, Inc.

SELECTED FINANCIAL ITEMS INAB

(in millions of USD)
CQ1 '23 CQ2 '23 CQ3 '23 CQ4 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (7.86) (7.72) (7.17) (7.93) (30.67)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (7.53) (7.72) (7.17) (7.60) (30.01)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 24.68 29.72 26.21 33.71 33.71
Cash & Short Term Investments 10.86 16.99 12.85 21.28 21.28
% of Assets 44% 57% 49% 63% 63%
Current Assets -Total 14.40 19.47 16.55 24.63 24.63
% of Assets 58% 65% 63% 73% 73%
Total Liabilities 7.89 7.92 8.45 8.77 8.77
% of Assets 32% 27% 32% 26% 26%
Current Liabilities - Total 3.75 3.78 4.69 5.39 5.39
% of Assets 15% 13% 18% 16% 16%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 16.79 21.80 17.76 24.94 24.94
% of Assets 68% 73% 68% 74% 74%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (7.44) (5.34) (5.71) (4.85) (23.34)
Net Cash Flow - Investing (0.43) (0.02) (0.08) (0.07) (0.60)
Net Cash Flow - Financing 0.55 11.49 1.65 13.35 27.04

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference